Skip to main content
Premium Trial:

Request an Annual Quote

Sigma s Q1 Sales Jump 10.8 Percent Amid R&D Spending Growth and Profit Decline

NEW YORK, April 26 (GenomeWeb News) - Sigma-Aldrich yesterday reported that first-quarter sales rose 10.8 percent as R&D spending grew 8.3 percent and net income shrank 10 percent.


Total receipts for the three months ended March 31 increased to $443 million from $400 million year over year.


R&D spending in the period grew to $13 million from $11.7 million in the year-ago period.


Profits in the first quarter declined to $66.5 million, or $.98 per diluted share, from $74.6 million, or $1.07 per diluted share, year over year.


Sigma said it had around $118.3 million in cash and equivalents as of March 31.

The Scan

Transcriptomic, Epigenetic Study Appears to Explain Anti-Viral Effects of TB Vaccine

Researchers report in Science Advances on an interferon signature and long-term shifts in monocyte cell DNA methylation in Bacille Calmette-Guérin-vaccinated infant samples.

DNA Storage Method Taps Into Gene Editing Technology

With a dual-plasmid system informed by gene editing, researchers re-wrote DNA sequences in E. coli to store Charles Dickens prose over hundreds of generations, as they recount in Science Advances.

Researchers Model Microbiome Dynamics in Effort to Understand Chronic Human Conditions

Investigators demonstrate in PLOS Computational Biology a computational method for following microbiome dynamics in the absence of longitudinally collected samples.

New Study Highlights Role of Genetics in ADHD

Researchers report in Nature Genetics on differences in genetic architecture between ADHD affecting children versus ADHD that persists into adulthood or is diagnosed in adults.